Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm and Anivive Lifesciences Sign Exclusive Global License Agreement for Verdinexor for Animal Health Applications
− Anivive Aims to Develop and Commercialize Verdinexor for the Treatment of Cancer in Companion Animals — − Karyopharm to Receive $1 Million Upfront Payment, Then Eligible to Receive Up To $43.5 Million in Future Milestones, Plus Royalties — NEWTON, Mass., May 03, 2017 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Karyopharm to Report First Quarter 2017 Financial Results on May 4, 2017
Conference Call Scheduled for Thursday, May 4, 2017 at 8:30 a.m. ET
View HTML
Toggle Summary Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
NEWTON, Mass. , April 25, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of a registered underwritten public offering of 3,902,439 shares of its common stock at a price to the public of $10.25 per share.
View HTML
Toggle Summary Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
NEWTON, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it is commencing a registered underwritten public offering of $40 million in shares of its common stock.
View HTML
Toggle Summary Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting
Selinexor Achieves Robust and Prolonged Response Rates in Patients with Relapsed or Refractory DLBCL, Including Against Both GCB and Non-GCB Subtypes 28.6% Overall Response Rate Demonstrated with a Median Duration of Greater than Seven Months Top-Line Data from SADAL Study Expected in Mid-2018
View HTML
Toggle Summary Karyopharm Announces Management Change
NEWTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin Renz, Executive Vice President, Chief Financial Officer and Treasurer, has stepped down in order to pursue other opportunities,
View HTML
Toggle Summary Karyopharm to Present Selinexor Phase 2b SADAL Data at the American Association for Cancer Research Annual Meeting 2017
Abstract Published Today Highlighting Interim Phase 2b SADAL Results in Patients with Relapsed or Refractory DLBCL Overall Response Rate Greater Than 28%, along with Additional Updated Data, to Be Presented in a Late-Breaking Poster at the Meeting NEWTON, Mass., March 31, 2017 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary U.S. FDA Division of Hematology Products Lifts Partial Clinical Hold on Karyopharm's Selinexor Clinical Trials
Recruitment Resumes Across All Selinexor Trials in Hematological Malignancies Timelines for Ongoing and Planned Studies Expected to Remain Materially Unchanged NEWTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company,
View HTML
Toggle Summary Karyopharm to Present at the 16th Annual Needham Healthcare Conference
NEWTON, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference in New York on Wednesday,
View HTML
Toggle Summary Karyopharm Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Selinexor Clinical Update
− Overall Response Rate of 28.4% Observed in Phase 2b SADAL Study in Relapsed/Refractory DLBCL; Additional Top-line Data to be Presented as a Late-Breaker at AACR 2017 Annual Meeting — − Company Announces FDA-Affirmed Development Path for Selinexor in DLBCL with Potential for Accelerated Approval —
View HTML